AR109898A1 - Perlas multicapa para uso farmacéutico - Google Patents
Perlas multicapa para uso farmacéuticoInfo
- Publication number
- AR109898A1 AR109898A1 ARP170102802A ARP170102802A AR109898A1 AR 109898 A1 AR109898 A1 AR 109898A1 AR P170102802 A ARP170102802 A AR P170102802A AR P170102802 A ARP170102802 A AR P170102802A AR 109898 A1 AR109898 A1 AR 109898A1
- Authority
- AR
- Argentina
- Prior art keywords
- drug
- polymer
- layer
- hept
- difluoro
- Prior art date
Links
- 239000011049 pearl Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 12
- 239000003814 drug Substances 0.000 abstract 12
- 229920000642 polymer Polymers 0.000 abstract 8
- 239000011324 bead Substances 0.000 abstract 3
- -1 keto prostaglandin Chemical class 0.000 abstract 3
- 230000004888 barrier function Effects 0.000 abstract 2
- 239000007771 core particle Substances 0.000 abstract 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 abstract 2
- 238000007789 sealing Methods 0.000 abstract 2
- WIUGSPUQKXSPDJ-JDFMTEHDSA-N (e)-7-[(1r,2r)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]hept-2-enoic acid Chemical compound CCCCC(F)(F)C(=O)CC[C@H]1CCC(=O)[C@@H]1CCCC\C=C\C(O)=O WIUGSPUQKXSPDJ-JDFMTEHDSA-N 0.000 abstract 1
- CTQWVWWSERVGET-HZPDHXFCSA-N 7-[(1r,2r)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]heptanoic acid Chemical compound CCCCC(F)(F)C(=O)CC[C@H]1CCC(=O)[C@@H]1CCCCCCC(O)=O CTQWVWWSERVGET-HZPDHXFCSA-N 0.000 abstract 1
- SDDSJMXGJNWMJY-BRHAQHMBSA-N 7-[(2r,4ar,5r,7ar)-2-[(3s)-1,1-difluoro-3-methylpentyl]-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid Chemical compound O1[C@](C(F)(F)C[C@@H](C)CC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 SDDSJMXGJNWMJY-BRHAQHMBSA-N 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 229930194542 Keto Natural products 0.000 abstract 1
- 229950005980 cobiprostone Drugs 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 abstract 1
- WGFOBBZOWHGYQH-MXHNKVEKSA-N lubiprostone Chemical compound O1[C@](C(F)(F)CCCC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 WGFOBBZOWHGYQH-MXHNKVEKSA-N 0.000 abstract 1
- 229960000345 lubiprostone Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- 239000007962 solid dispersion Substances 0.000 abstract 1
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 abstract 1
- 229950008081 unoprostone isopropyl Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se divulgan perlas multicapa para uso farmacéutico que tienen una capa de fármaco en polímero. Las perlas multicapa divulgadas para uso farmacéutico tienen (a) una partícula de núcleo; (b) una capa de barrera opcional que recubre la superficie de la partícula de núcleo; (c) una capa de fármaco en polímero que recubre la superficie del núcleo o la capa de barrera, (d) una capa selladora opcional que recubre la superficie de la capa de fármaco en polímero; y (e) opcionalmente una o más capas exteriores externas a la capa de fármaco en polímero o la capa selladora. La capa de fármaco en polímero consiste esencialmente en (i) un fármaco seleccionado del grupo que consiste en un fármaco de 15-ceto prostaglandina, un fármaco de 13,14-dihidro prostaglandina, y un fármaco de 13,14-dihidro-15-ceto prostaglandina; y (ii) un polímero seleccionado del grupo que consiste en polivinilpirrolidona, copolímero de vinilpirrolidona-vinilacetato o una de sus mezclas. La capa de fármaco en polímero puede ser una dispersión sólida del fármaco en el polímero. Se divulgan además composiciones farmacéuticas que comprenden una pluralidad de perlas multicapa y un excipiente farmacéuticamente aceptable y métodos de tratamiento de un trastorno gastrointestinal. Reivindicación 2: Una perla multicapa de la reivindicación 1, donde el fármaco es seleccionado del grupo que consiste en: ácido (-)-7-[(2R,4aR,5R,7aR)-2-(1,1-difluorpentil)-2-hidroxi-6-oxooctahidrociclopenta[b]piran-5-il]heptanoico (lubiprostona); ácido (-)-7-{(2R,4aR,5R,7aR)-2-[(3S)-1,1-difluoro-3-metilpentil]-2-hidroxi-6-oxooctahidrociclopenta[b]piran-5-il}heptanoico (cobiprostona); (+)-isopropil (Z)-7-[(1R,2R,3R,5S)-3,5-dihidroxi-2-(3-oxodecil)ciclopentil]hept-5-enoato, (isopropil unoprostona); ácido (Z)-7-[(1R,2R,3R,5S)-3,5-dihidroxi-2-(3-oxodecil)ciclopentil]hept-5-enoico; ácido (-)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctil)-5-oxociclopentil]heptanoico; y ácido (E)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctil)-5-oxociclopentil]hept-2-enoico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662405131P | 2016-10-06 | 2016-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109898A1 true AR109898A1 (es) | 2019-02-06 |
Family
ID=60543581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102802A AR109898A1 (es) | 2016-10-06 | 2017-10-06 | Perlas multicapa para uso farmacéutico |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11534404B2 (es) |
| JP (1) | JP6957610B2 (es) |
| AR (1) | AR109898A1 (es) |
| TW (1) | TW201815383A (es) |
| WO (1) | WO2018065826A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11534404B2 (en) | 2016-10-06 | 2022-12-27 | Sucampo Ag | Multilayer beads for pharmaceutical use |
| MX392727B (es) * | 2016-12-09 | 2025-03-24 | Bayer Animal Health Gmbh | Preparación framaceútica de estructura multicapa y método para su fabricación |
| JPWO2019221215A1 (ja) * | 2018-05-18 | 2021-05-27 | ニプロ株式会社 | ルビプロストン含有粒子状医薬組成物 |
| CN109701461B (zh) * | 2018-10-25 | 2021-06-08 | 西南交通大学 | 一种基于PEG/Dex双水相的碳酸钙/海藻酸钙复合微囊的制备及其应用 |
| JP2020075874A (ja) * | 2018-11-06 | 2020-05-21 | ニプロ株式会社 | ルビプロストン含有フィルム状医薬組成物 |
| WO2020180690A1 (en) * | 2019-03-01 | 2020-09-10 | Avadel Legacy Pharmaceuticals, Llc | Liquid pharmaceutical compositions with stable drug release profiles |
| JP7518661B2 (ja) * | 2020-05-14 | 2024-07-18 | 沢井製薬株式会社 | ルビプロストン含有整粒物、ルビプロストン含有錠剤およびそれらの製造方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5942313A (ja) * | 1982-09-01 | 1984-03-08 | Teijin Ltd | ポリビニルポリピロリドンを用いた製剤 |
| JPS6377821A (ja) * | 1986-09-19 | 1988-04-08 | Teikoku Seiyaku Kk | 安定なプロスタグランジンｅ組成物 |
| US5317032A (en) | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
| DK0503887T3 (da) * | 1991-03-14 | 1996-09-16 | R Tech Ueno Ltd | Fremme af sårheling med 15-ketoprostaglandinforbindelser |
| PT1426361E (pt) | 1999-10-15 | 2008-10-08 | Sucampo Ag | Nova composição contendo um composto bicíclico e um glicérido |
| DE19962544A1 (de) | 1999-12-23 | 2001-07-19 | Degussa | Verfahren zum Beschichten eines keramischen Wabenkörpers |
| AU4472701A (en) * | 2000-04-06 | 2001-10-23 | Sucampo Ag | Bile secretion promoting composition |
| US6414016B1 (en) | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
| TWI302100B (en) | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
| BR0209863A (pt) | 2001-05-18 | 2004-06-08 | Sucampo Ag | Composição catártica |
| EP1420794B1 (en) | 2001-08-31 | 2017-12-27 | Sucampo AG | Prostaglandin analogs as chloride channel openers |
| JP2005139085A (ja) * | 2003-11-04 | 2005-06-02 | Ono Pharmaceut Co Ltd | 顆粒 |
| EP1863453A2 (en) * | 2005-03-29 | 2007-12-12 | Evonik Röhm GmbH | Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release |
| CN104983712A (zh) | 2006-01-24 | 2015-10-21 | 株式会社·R-技术上野 | 软明胶胶囊制剂 |
| CN101511346B (zh) * | 2006-09-04 | 2012-07-04 | 万能药生物有限公司 | 可编制的漂浮递送技术 |
| CN101318948B (zh) * | 2008-04-01 | 2011-04-27 | 上海天伟生物制药有限公司 | 鲁比前列酮晶体、其制备方法及用途 |
| US20120208773A1 (en) * | 2008-08-12 | 2012-08-16 | Valeant International (Barbados) Srl | Pharmaceutical compositions with tetrabenazine |
| WO2010038691A1 (ja) * | 2008-09-30 | 2010-04-08 | アステラス製薬株式会社 | 経口投与用粒子状医薬組成物 |
| CA2757979A1 (en) * | 2009-04-09 | 2010-10-14 | Alkermes Pharma Ireland Limited | Controlled-release clozapine compositions |
| EP2464340A2 (en) * | 2009-08-12 | 2012-06-20 | Valeant International (Barbados) SRL | Pharmaceutical compositions with tetrabenazine |
| UA119335C2 (uk) * | 2013-12-11 | 2019-06-10 | Айронвуд Фармасьютикалз, Інк. | Композиції лінаклотиду з затриманим вивільненням |
| US20160120840A1 (en) | 2014-10-30 | 2016-05-05 | Sucampo Ag | Method and composition for treating nonerosive reflux disease |
| US20170348263A1 (en) * | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
| US11534404B2 (en) | 2016-10-06 | 2022-12-27 | Sucampo Ag | Multilayer beads for pharmaceutical use |
-
2017
- 2017-10-05 US US16/338,948 patent/US11534404B2/en active Active
- 2017-10-05 JP JP2019516182A patent/JP6957610B2/ja active Active
- 2017-10-05 WO PCT/IB2017/001383 patent/WO2018065826A1/en not_active Ceased
- 2017-10-06 AR ARP170102802A patent/AR109898A1/es unknown
- 2017-10-06 TW TW106134584A patent/TW201815383A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201815383A (zh) | 2018-05-01 |
| US20200390708A1 (en) | 2020-12-17 |
| JP2019529467A (ja) | 2019-10-17 |
| US11534404B2 (en) | 2022-12-27 |
| JP6957610B2 (ja) | 2021-11-02 |
| WO2018065826A1 (en) | 2018-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109898A1 (es) | Perlas multicapa para uso farmacéutico | |
| JP2014528431A5 (es) | ||
| ES2526092T3 (es) | Formulaciones de olanzapina en nanopartículas inyectables | |
| WO2011123836A3 (en) | Pharmaceutical formulations for the treatment of overactive bladder | |
| EA200900264A1 (ru) | Композиции флибансерина и способ их приготовления | |
| JP2016512833A (ja) | ウイルス感染症の治療薬としてのベラプロスト異性体 | |
| RU2014124184A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и модулятора пути янус-киназы 2 - проводника сигнала и активатора транскрипции 5 | |
| JP2019529467A5 (es) | ||
| JP2014503523A5 (es) | ||
| EA200900270A1 (ru) | Системы регулируемого высвобождения и способ их приготовления | |
| AR075148A1 (es) | Formulacion de rasagilina de liberacion retardada. proceso para fabricar citrato de rasagilina | |
| HRP20192026T1 (hr) | Formulacija tableta od neratinib maleata | |
| WO2011106729A3 (en) | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents | |
| BR112012016460A2 (pt) | diazóxido ou um sal farmaceuticamente aceitável deste e método para sua utilização no tratamento de uma doença desmielinizante autoimune do sistema nervoso central (cns), e composição farmacêutica. | |
| WO2014027334A3 (es) | Composicion farmacéutica oral en forma de microesferas y proceso de elaboración | |
| CN102655859A (zh) | 病毒感染的组合疗法治疗 | |
| NZ714517A (en) | Delayed release cysteamine bead formulation | |
| PH12014502609B1 (en) | Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug | |
| JP2017528497A5 (es) | ||
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| JP2016513650A5 (es) | ||
| US20220362387A1 (en) | Senolytic and antiinflammatory prodrugs and methods of use thereof | |
| CA2794655A1 (en) | Method for treating schizophrenia and related diseases | |
| AR038141A1 (es) | Composiciones farmaceuticas estables que comprenden inhibidor(es) de ace | |
| MX2021016093A (es) | Composicion farmaceutica para tratar un tumor. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |